The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study

BackgroundTetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes.ObjectiveTo assess the 12-week of oral tetracyclines a rifampicin.MethodsA prospective, international cohort study performed between October 2018 August 2019.ResultsIn total, 63.6% included 283 patients received tetracyclines, 36.4% were treated with rifampicin. Both groups showed significant decrease International Hidradenitis Suppurativa Severity Score System baseline (both P < .001). The Clinical Response (HiSCR) was achieved 40.1% 48.2% patients, respectively (P = .26). Patient characteristics or disease severity not associated attainment HiSCR minimal clinically important differences Dermatology Life Quality Index pain.LimitationsCohort study. Respectively, 23.9% 19.4% had to be excluded analysis tetracycline group because low abscess nodule count at baseline.ConclusionThis shows treatment after 12 weeks suppurativa. No observed 2 treatments, regardless severity. Tetracyclines outcomes. To A 2019. In pain. Cohort baseline. This